RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:News! Warrants 0.30 extended. I read the words but the logistics dont make sense. The 180 day visit is ONLY for administering the 2nd treatment..... there cant be a checkup like a common cold...... doctors have to administer the cystoscopies to get a full picture.......... Also P345 are due for their 2nd treatment in May..........Patient 1 March 3rd or before absolutely made it under the wire before covid protocols came in.....P2 was the only question as the march nr said yes to 2nd treatment but late April said no. Because P2 fell April 7 or before........ why is everyone under a spell of amnesia........
enriquesuave wrote: Could it be that when they saw 1st 2 patients all clear at 6 months visit and thus for possibly a 2nd treatment, they decided that it was not worth risking to bring patients in for follow up visits as there would be good chances that they would also be CR? That would mean extreme confidence by Principal investigators IMO. Just a guess, but that would be awesome after all patients 5&6 from PH1 only had one treatment and were CR for at least 18 months. Anything is possible. I am probably wrong somewhere, but who knows?
jojomarch wrote: Thanks Thor and Vestor . I guess i will put my trust in TLT management , like for the last +5 years . Let us hope for re commencement .
GLTA
vestor111 wrote: Hey Thor I have been looking for this update but can't seem to find it.
This was in the quarterly "update":
"...nor will any existing patient currently enrolled in the clinical study be treated a second time or be assessed by the Principal Investigator (“PI”) for their follow up visits, until the clinical study sites re-commence operations."
and this is from the financial NR:
- Clinical study sites status. Canadian clinical study sites are currently on hold for patient enrolment, treatment and follow-up due to the current COVID-19 pandemic. Theralase will continue to monitor the COVID-19 pandemic, provincial and federal guidelines in order to manage its business in compliance with all health and safety best practices. No new patients will be enrolled or treated at any Canadian clinical study site, nor will any existing patient currently enrolled in the clinical study be treated a second time or be assessed by a Principal Investigator ("PI") for their follow up visits, until the clinical study sites re-commence operation. Theralase is in constant communication with all Canadian clinical study sites for any update on re-commencing patient enrollment and treatment activities.
Could you provide a link to this update? (not on SH or company website.)